Source comparison
CJC-1295 Legal 2026 Status: Research vs Therapeutic Use
In vitro cell culture studies Legal. No FDA approval required for laboratory reagents Unrestricted from research suppliers Institutional purchase order or academic affiliation documentation Low Animal pharmacokinetic research Legal under IACUC-approved protoco
This comparison does not assign a generated winner or score.
- In vitro cell culture studies
- Legal. No FDA approval required for laboratory reagents
- Unrestricted from research suppliers
- Institutional purchase order or academic affiliation documentation
- Low
- Animal pharmacokinetic research
- Legal under IACUC-approved protocols
- Available with protocol documentation
- IACUC protocol number + institutional letterhead
- Human clinical trial (IND filed)
- Legal under FDA Investigational New Drug exemption
- Restricted to IND holders only
- Active IND number + Phase I/II/III protocol approval
- Low (if compliant)
- Compounded prescription for patients
- Illegal. Violates FDCA § 331(d) as unapproved new drug
- Effectively zero as of 2025 enforcement wave
- None (activity is prohibited)
- High (regulatory + legal liability)
- Personal use without prescription
- Illegal in 12 states; federally unenforced but high-risk
- Gray market only (no legitimate suppliers)
- Not applicable (prohibited activity)
- Very High
- The practical takeaway: CJC-1295 legal 2026 status permits possession and use strictly within research contexts. University labs, biotech R&D facilities, and contract research organizations operating under proper institutional oversight. Any other use exists outside regulatory compliance and exposes the user to enforcement risk that has escalated significantly since 2023.